Advertisement
Canada markets close in 4 hours 46 minutes

  • S&P/TSX

    21,920.21
    +34.83 (+0.16%)
     

  • S&P 500

    5,096.16
    +47.74 (+0.95%)
     

  • DOW

    38,157.64
    +71.84 (+0.19%)
     

  • CAD/USD

    0.7303
    -0.0020 (-0.27%)
     

  • CRUDE OIL

    83.59
    +0.02 (+0.02%)
     

  • Bitcoin CAD

    87,177.77
    +301.94 (+0.35%)
     

  • CMC Crypto 200

    1,328.53
    -68.00 (-4.87%)
     

  • GOLD FUTURES

    2,346.70
    +4.20 (+0.18%)
     

  • RUSSELL 2000

    1,997.82
    +16.71 (+0.84%)
     

  • 10-Yr Bond

    4.6610
    -0.0450 (-0.96%)
     

  • NASDAQ

    15,914.74
    +302.98 (+1.94%)
     

  • VOLATILITY

    15.33
    -0.04 (-0.26%)
     

  • FTSE

    8,138.94
    +60.08 (+0.74%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6839
    +0.0018 (+0.26%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Mexico approves emergency use of Lilly's COVID-19 treatment

Reuters

MEXICO CITY, Dec 1 (Reuters) - Mexico's health regulator Cofepris said on Wednesday it had approved U.S. pharmaceutical firm Eli Lilly and Co's antibody treatment against COVID-19 for emergency use with infected patients at risk from comorbidities.

Cofepris said in a statement it had granted the emergency use of Lilly's injectable combination of bamlanivimab and etesevimab to treat mild to moderate cases of coronavirus in people above the age of 12 who weigh at least 40 kilograms.

The U.S. Food and Drug Administration had previously approved emergency use of the combination.

Cofepris noted that the Lily antibody treatment does not replace licensed COVID-19 vaccines. (Reporting by Raul Cortes Editing by Chizu Nomiyama)